WO1999006421A1 - Synthetic insulin mimetic substances - Google Patents
Synthetic insulin mimetic substances Download PDFInfo
- Publication number
- WO1999006421A1 WO1999006421A1 PCT/US1998/015383 US9815383W WO9906421A1 WO 1999006421 A1 WO1999006421 A1 WO 1999006421A1 US 9815383 W US9815383 W US 9815383W WO 9906421 A1 WO9906421 A1 WO 9906421A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- compound
- amino
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
Definitions
- This invention relates to compounds of the formula (I)
- (I) and pharmaceutical compositions containing them mimic the action of insulin and are useful for the treatment of disorders of glucose metabolism, such as impaired glucose tolerance, elevated blood glucose associated with type II diabetes and insulin resistance.
- Physiological conditions known in the art to be associated with insulin resistance include: diabetes mellitus and its chronic complications; obesity; hyperlipidemia and dvslipidemia; atherosclerosis; hypertension; cardiovascular disease; AIDS; cancer; wasting/cachexia; sepsis; trauma associated with burns, malnutrition and/or stress; aging; lupus and other autoimmune diseases; endocrine disease; hyperuricemia; polycystic ovary syndrome; and complications arising from athletic activity or inactivity.
- Insulin mimetic molecules extracted from biological sources present a variety of undesirable characteristics, including possible contamination as well as unreliable or limited sources of supply of naturally occurring molecules. It is therefore desirable to devise a synthetic molecule which mimics the activity of insulin or its mediators and which can be synthesized without resort to extracts from animal tissue.
- a first embodiment of the present invention is therefore directed to compounds of the formula (I)
- amino disaccharides of the present invention include molecules consisting of galactosamine and isomers and derivatives of inositol, such as 2-deoxy-2-amino-galactopyranosyl pinitol and derivatives of these amino disaccharides.
- a second embodiment of the present invention is directed to pharmaceutical compositions containing the inventive compounds. These pharmaceutical compositions are useful for treating disorders of glucose metabolism, such as impaired glucose tolerance, elevated blood glucose associated with Type II diabetes, and insulin resistance and physiological conditions associated therewith.
- FIG. 1 is an illustration of the numbering system used to describe compounds of the present invention.
- FIGS. 2 through 7 illustrate exemplary synthetic pathways used to prepare compounds of the present invention.
- the present invention is directed to compounds of the formula (I)
- R,-R 2 are each independently selected from the group consisting of:
- R,-R 2 and the nitrogen atom to which they are bonded may together form a heterocyclic group;
- R--R 10 are each independently selected from the group consisting of:
- alkyl group straight or branched chain, having 1 to 24 carbon atoms, such as methyl, ethyl, propyl, t-butyl, pentyl, octyl and dodecyl;
- a cycloalkyl group having 3 to 10 carbon atoms such as cyclopropyl, cyclopentyl and cyclohexyl;
- (k) a heterocyclic group having 2 to 9 carbon atoms and at least one heteroatom selected from the group consisting of oxygen, sulfur and nitrogen; or any adjacent two of R 3 -R 10 may together form a cycloalkyl group or heterocyclic group; and
- X, and X 2 are each independently selected from the group consisting of an oxygen atom, a sulfur atom and a nitrogen atom.
- Alkoxy (b), aryloxy (f), and ester (i-j) substituents are useful in protecting the molecule, modifying its hydrophilicity and/or modulating its insulin mimetic properties and so are particularly preferred substituents.
- R, and R 2 are each a hydrogen atom or a lower alkyl group having from 1 to 4 carbon atoms, such as methyl or ethyl. More preferably, R, and R 2 are each a hydrogen atom.
- X, and X 2 are each an oxygen atom. More preferably, when X, and X 2 are each an oxygen atom, the hexosamine component of the inventive compounds is selected from the group consisting of 2-deoxy-2-amino- ⁇ -D- galactose and 2-deoxy-2-amino- ⁇ -D-glucose. Most preferably, the hexosamine component is 2-deoxy-2-amino- ⁇ -D-galactose.
- the inositol component of the inventive compounds is selected from the group consisting of /wyo-inositol and tJzz ' ro-inositol. More preferably, the inositol component is c/zz ' ro-inositol, i.e., compounds of the formula (II) wherein RrR 10 and X, and X 2 are as defined above.
- At least one of R 3 -R g is selected from the group consisting of an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group, a carboxyalkyl group, or a carboxyaryl group. More preferably, at least one of R 3 -R 8 is an alkyl group. Most preferably, R 8 is a methyl group.
- the compounds of the present invention may be prepared according to any of the methods known to those skilled in the art.
- the compounds of this invention can be prepared in the following manner.
- the beta-glycosides of 2-deoxy-2-amino sugars with derivatives of inositol of this invention are prepared by the reaction of an appropriately protected amino sugar precursor having a leaving group at the 1 -position (glycosyl donor) with a free hydroxyl group of a suitably protected inositol (glycosyl acceptor) in the presence of a promoter, followed by deprotection.
- an appropriately protected amino sugar precursor having a leaving group at the 1 -position (glycosyl donor)
- a free hydroxyl group of a suitably protected inositol (glycosyl acceptor) in the presence of a promoter
- 4'-O-(2-deoxy-2- amino- ⁇ -D-galactopyranosyl)-D-pinitol is prepared by the glycosylation/deprotection sequence shown in Scheme 1 , which is set forth in FIG.
- glycosyl donor l-bromo-l,2-dideoxy-3,4,6-tri-0-acetyl-2-dinitro- phenylaminogalactose
- glycosyl donors are prepared by straight forward synthetic manipulation of available precursors. For instance, selective derivatization of the 4-position of galactal can be achieved by treating the compound with 2 equivalents of t-butyldimethylsilyl chloride as shown in Scheme 3, which is set forth in FIG. 4. Compound A can be easily converted to an ether or ester by known Williamson or Schotten-Bauman techniques.
- Azidonitration and bromide displacement on B provides a glycosyl donor which, following reaction with a glycosyl acceptor in the presence of silver silicate, reduction of the azido group by hydrogenation and deprotection with fluoride, yields a beta-glycoside of 2deoxy-2-aminogalactose substituted at the 4-position with an ether or an ester.
- glycosyl acceptor l',2'; 5',6'-di-O-isopropylidene-D-pinitol, used in the synthesis of 4'-O-(2-deoxy-2-amino- ⁇ -D-galacopyranosyl)-D-pinitol as in Scheme 1 was prepared by the reaction of D-pinitol with dimethoxypropane in the presence of a catalytic amount of p-toluenesulfonic acid.
- Other glycosyl acceptors can be prepared readily.
- compounds E and F which can be prepared as shown in Scheme 6, which is set forth in FIG. 6, can be mono or dialkylated regioselectivly using Williamson techniques.
- Glycosides containing c z ro-inositols with alkoxy substituents at the 2 and 6 positions can be obtained by catalytic debenzylation of G to give glycosyl acceptor H as set forth in FIG. 7, followed by glycosylation of H and deprotection using standard techniques.
- glycosides containing c/ ⁇ V ⁇ -inositols with alkoxy substituents at the 1 and 5- positions can be prepared from G.
- a second preferred embodiment of the present invention is therefore directed to pharmaceutical compositions containing the inventive compounds described above.
- compositions of the present invention will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the inventive compounds alone), the site of delivery of the pharmaceutical composition, the method of administration, the scheduling of administration, and other factors known to practitioners.
- the "effective amount" of a compound of the present invention for pharmaceutical purposes is thus determined by such considerations.
- the total pharmaceutically effective amount of a disaccharide of the present invention administered per dose will be in the range of about 10 ⁇ g/kg/day to 100 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.1 mg/kg/day, and most preferably for humans between about 0.1 and 10 mg kg/day.
- the compound of the present invention is typically administered parenterally at a dose rate of about 100 ⁇ g/kg/hour to about 500 ⁇ g " kg/hour, either by 1-4 injections per day or by continuous subcutaneous irifusions, for example, using a mini-pump.
- An intravenous bag solution may also be employed.
- the key factor in selecting an appropriate dose is the result obtained, as measured by increases in insulin-like activity in the patient. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
- compositions containing the compounds of the invention may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray.
- pharmaceutically acceptable carrier is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
- the compounds of the present invention are also suitably administered by sustained-release systems.
- sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules.
- Sustained-release matrices include polylactides (U.S. Pat. No. 3.773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L- glutamate (Sidman et al, Biopolymers 22:541-556 (1983)). poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 75:167-277 (1981), and Langer, Chem. Tech.
- Sustained-release compositions also include liposomally entrapped compounds.
- Liposomes containing one or more of the compounds of the present invention may be prepared by methods known je r se: DE 3,218,121; Epstein et al, Proc. Natl. Acad. Sci. (USA) 52:3688-3692 (1985); Hwang et al, Proc. Natl. Acad. Sci. (USA) 77:4030-4034
- the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal therapy.
- the compound of the present invention is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- a pharmaceutically acceptable carrier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to carbohydrates.
- the formulations are prepared by contacting the compound of the present invention uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
- the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non- aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
- the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
- additives such as substances that enhance isotonicity and chemical stability.
- Such materials are non- toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbi
- the compound of the present invention is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml. preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers may result in the formation of salts depending upon the particular substitutent(s) on the disaccharide.
- the compound of the present invention ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
- a lyophilized formulation 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous disaccahride solution, and the resulting mixture is lyophilized.
- the infusion solution is prepared by reconstituting the lyophilized disaccharide using bacteriostatic Water-for-Injection.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Associated with such container s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- the compounds of the present invention may be employed in conjunction with other therapeutic compounds.
- the following examples are illustrative only and are not intended to limit the scope of the invention as defined by the appended claims. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
- D-c/7ro-inositol (37.5mg) was stirred with 3.5 ml of 1 M aqueous lithium hydroxide and 7 ml of dioxan and heated to 90°C for 28 hours.
- Acetic acid (4 ml) was added to pH S and the solvents were removed in vacuo.
- the residue was dissolved in methanol, 1 g of silica gel 60 was added and the methanol was removed in vacuo.
- the preabsorbed material was loaded on a 1 X 15 cm flash column packed with silica gel 60 and the column was eluted with 3: 1 chloroform:isopropanol to isolate 22.1 mg of the product (90%).
- Vacuum dried l-bromo-l,2-dideoxy-3,4,6-tri-O-acetyl-2- dinitrophenylamino-galactose (3.9 g) and 1 g of l,2;5,6-di-O-isopropylidene-D- pinitol were dissolved in 100 ml of dry methylene chloride and the solution stirred at room temperature. Under a nitrogen shroud, freshly activated 4 angstrom powdered molecular sieves was added and the mixture stirred for one hour.
- the crude material was loaded on a 2 X 10 cm flash column packed with silica gel 60 and eluted with 3:1 chloroformisopropanol to yield 361 mg (610-.) of the product, which was recrystallized from isopropanol to yield 74 mg of crystalline product.
- the residue was passed through a C-18 Millipore cartridge and eluted with acetonitrile.
- the residue (which weighed 64 mg) was recrystallized from isopropanol to yield 25 mg of the product.
- rats were injected intravenously with 70 mg/kg of streptozotocin. After ten days, when resultant hyperglycemia was established, the animals were anesthetized with ketamine and zero time blood glucose levels were established by way of tail vein sampling.
- An experimental group was given 2 mg " kg 4'-O-(2-deoxy-2-amino- ⁇ -D-galactopyranosyl)-D-pinitol by intravenous injection via the tail vein, and a control group was given an equal volume of saline. Blood glucose levels were measured over time in both groups. All measurements were made while the subjects were under ketamine anesthesia.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98937080A EP1000077A1 (en) | 1997-07-29 | 1998-07-29 | Synthetic insulin mimetic substances |
CA002297755A CA2297755A1 (en) | 1997-07-29 | 1998-07-29 | Synthetic insulin mimetic substances |
JP2000505177A JP2001512130A (en) | 1997-07-29 | 1998-07-29 | Synthetic insulin mimic |
AU85872/98A AU8587298A (en) | 1997-07-29 | 1998-07-29 | Synthetic insulin mimetic substances |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/902,338 US6093697A (en) | 1994-11-07 | 1997-07-29 | Synthetic insulin mimetic substances |
US08/902,338 | 1997-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006421A1 true WO1999006421A1 (en) | 1999-02-11 |
Family
ID=25415711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015383 WO1999006421A1 (en) | 1997-07-29 | 1998-07-29 | Synthetic insulin mimetic substances |
Country Status (7)
Country | Link |
---|---|
US (1) | US6093697A (en) |
EP (1) | EP1000077A1 (en) |
JP (1) | JP2001512130A (en) |
AU (1) | AU8587298A (en) |
CA (1) | CA2297755A1 (en) |
TW (1) | TW467908B (en) |
WO (1) | WO1999006421A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000673A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
WO2002000674A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
FR2835527A1 (en) * | 2002-02-05 | 2003-08-08 | Centre Nat Rech Scient | SYNTHESIS OF GLYCAN INOSITOLPHOSPHATE-LIKE MOLECULES: TREATMENT OF CELL PROLIFERATION AND METABOLIC DISORDERS CHARACTERIZED BY INSULIN RESISTANCE |
US6716826B2 (en) | 2000-05-12 | 2004-04-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6759390B2 (en) | 2000-05-12 | 2004-07-06 | Manuel Martin-Lomas | Compounds and their uses |
US6939857B2 (en) | 2000-05-12 | 2005-09-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6953781B2 (en) | 2000-05-12 | 2005-10-11 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
WO2008080064A1 (en) * | 2006-12-21 | 2008-07-03 | Trustees Of Tufts College | Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6492341B1 (en) * | 1997-05-07 | 2002-12-10 | Cornell Research Foundation, Inc. | Preparation of fagopyritols and uses therefor |
WO2002085406A1 (en) * | 2001-04-24 | 2002-10-31 | Restoragen, Inc. | Methods and compositions for treating conditions associated with insulin resistance |
WO2004037974A2 (en) * | 2002-05-09 | 2004-05-06 | Cornell Research Foundation, Inc. | Fagopyritol synthase genes and uses thereof |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US8703719B1 (en) | 2009-05-18 | 2014-04-22 | Bio-Engineered Supplements And Nutrition, Inc. | Method and composition for improved muscle performance |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014075A1 (en) * | 1994-11-07 | 1996-05-17 | University Of Virginia Patent Foundation | Synthetic insulin mimetic substances |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) * | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) * | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
US4446064A (en) * | 1980-12-19 | 1984-05-01 | The University Of Virginia Alumni Patents Foundation | Insulin mediator substance |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
DE3374837D1 (en) * | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (en) * | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Pharmaceutical compositions for tumour treatment |
EP0102324A3 (en) * | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) * | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE159858T1 (en) * | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLULAR AND HUMORAL IMMUNE DEFENSE |
US4615885A (en) * | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4906468A (en) * | 1986-04-11 | 1990-03-06 | The Rockefeller University | Insulin activity messengers, their antibodies, and thereof |
JP2504289B2 (en) * | 1990-05-21 | 1996-06-05 | 宇部興産株式会社 | Rear stock for extrusion presses Tailstock of substretcher |
-
1997
- 1997-07-29 US US08/902,338 patent/US6093697A/en not_active Expired - Fee Related
-
1998
- 1998-07-29 CA CA002297755A patent/CA2297755A1/en not_active Abandoned
- 1998-07-29 EP EP98937080A patent/EP1000077A1/en not_active Withdrawn
- 1998-07-29 AU AU85872/98A patent/AU8587298A/en not_active Abandoned
- 1998-07-29 JP JP2000505177A patent/JP2001512130A/en not_active Withdrawn
- 1998-07-29 WO PCT/US1998/015383 patent/WO1999006421A1/en not_active Application Discontinuation
- 1998-10-23 TW TW087112488A patent/TW467908B/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014075A1 (en) * | 1994-11-07 | 1996-05-17 | University Of Virginia Patent Foundation | Synthetic insulin mimetic substances |
Non-Patent Citations (2)
Title |
---|
BERLIN, WILLIAM K.; ZHANG, WEN SHENG; SHEN, T. Y.: "Glycosylinositol derivatives. III. Synthesis of hexosamine inositol phosphates related to putative insulin mediators", TETRAHEDRON, vol. 47, no. 1, 1991, pages 1 - 20, XP002088795 * |
HEINZ, DIRK W.; RYAN, MARGRET; SMITH, MILES P.; WEAVER, LARRY H.; KEANA, JOHN F. W.; GRIFFITH, O. HAYES: "Crystal Structure of Phosphatidylinositol-Specific Phospholipase C from Bacillus cereus in Complex with Glucosaminyl(alpha 1->6)-D-myo-inositol, an Essential Fragment of GPI Anchors", BIOCHEMISTRY, vol. 35, no. 29, 1996, pages 9496 - 9504, XP002088796 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716826B2 (en) | 2000-05-12 | 2004-04-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6759390B2 (en) | 2000-05-12 | 2004-07-06 | Manuel Martin-Lomas | Compounds and their uses |
US6939857B2 (en) | 2000-05-12 | 2005-09-06 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US6953781B2 (en) | 2000-05-12 | 2005-10-11 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
US7235533B2 (en) | 2000-05-12 | 2007-06-26 | Rodaris Pharmaceuticals Limited | Compounds and their uses |
WO2002000673A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
WO2002000674A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
FR2835527A1 (en) * | 2002-02-05 | 2003-08-08 | Centre Nat Rech Scient | SYNTHESIS OF GLYCAN INOSITOLPHOSPHATE-LIKE MOLECULES: TREATMENT OF CELL PROLIFERATION AND METABOLIC DISORDERS CHARACTERIZED BY INSULIN RESISTANCE |
WO2003066647A2 (en) * | 2002-02-05 | 2003-08-14 | (Cnrs) Centre National De Recherche Scientifique | Synthesis of inositolphosphate glycan molecules: treatment of cell proliferation disorders and metabolic disorders characterized by insulin resistance |
WO2003066647A3 (en) * | 2002-02-05 | 2004-03-25 | Cnrs Ct Nat De Rech Scient | Synthesis of inositolphosphate glycan molecules: treatment of cell proliferation disorders and metabolic disorders characterized by insulin resistance |
WO2008080064A1 (en) * | 2006-12-21 | 2008-07-03 | Trustees Of Tufts College | Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders |
EP2324837A1 (en) * | 2006-12-21 | 2011-05-25 | Trustees Of Tufts College | Synthetic lipophilic inositol glycans for treatment of glucose-metabolism disorders |
Also Published As
Publication number | Publication date |
---|---|
AU8587298A (en) | 1999-02-22 |
TW467908B (en) | 2001-12-11 |
JP2001512130A (en) | 2001-08-21 |
US6093697A (en) | 2000-07-25 |
EP1000077A1 (en) | 2000-05-17 |
CA2297755A1 (en) | 1999-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2170738C2 (en) | Substituted liposaccharides used for treatment and prophylaxis of endotoxicosis | |
US6093697A (en) | Synthetic insulin mimetic substances | |
AU684466B2 (en) | Novel medicinal composition | |
US5731292A (en) | Dihydrochalcone derivatives which are hypoglycemic agents | |
US4474806A (en) | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents | |
US5185436A (en) | Esters of normal butyric acid and their use as pharmaceuticals | |
US5652221A (en) | Method of treating defective glucose metabolism using synthetic insulin substances | |
JPS60224697A (en) | Tigogenin serobioside and medicine | |
CA2079971A1 (en) | Anti-endotoxin compounds and related molecules and methods | |
HU199860B (en) | Process for producing ganglioside derivatives and pharmaceutical compositions comprising such active ingredient | |
US5498604A (en) | Lewis-type sugar chain derivative | |
HU209561B (en) | Process for preparing pharmaceutical preparations containing n-(dichloro-acetyl)-sphingosine or n-(dichloro-acetyl)-dihydro-sphingosine as active ingredients | |
SE468987B (en) | NEW RETINOIDS OF THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS THEREOF | |
CA2340649A1 (en) | Phosphoglycolipid and methods for its use | |
US5441932A (en) | Sugar compounds for inhibition of the biosynthesis of sugar chains containing sialic acid | |
US4888417A (en) | Therapeutic and prophylactic agents for peptic ulcer | |
US4503045A (en) | 2'-Deoxy-3',5'-di-O-alkylcarbonyl-5-fluorouridine derivatives, a process for the preparation of the derivatives and anti-tumor agents containing the derivatives | |
JPH023800B2 (en) | ||
US5120835A (en) | Saccharide derivatives of protocatechualdehyde | |
JPH02111785A (en) | Sphingo glycolipid | |
FR2970969A1 (en) | OLIGOSACCHARIDES 3-O-ALKYL ACTIVATORS OF FGFS RECEPTORS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
US4686206A (en) | Composition for activating function of phagocytes | |
US4551446A (en) | Use of synthetic phosphoglycerides possessing platelet activating properties as desensitizing agents | |
US4061766A (en) | Cyclopentane derivatives and process for preparing them | |
GB2211503A (en) | New saccharides, their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2297755 Country of ref document: CA Ref country code: CA Ref document number: 2297755 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 85872/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998937080 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998937080 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998937080 Country of ref document: EP |